New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
14:02 EDTPCRXPacira Pharmaceuticals reports positive results from studies of EXPAREL
Pacira Pharmaceuticals announced new data evaluating the use of EXPAREL to manage postsurgical pain following total joint arthroplasty, which included hip and knee replacement surgery. The data, derived from two studies presented at the 81st annual meeting of the American Academy of Orthopedic Surgeons, demonstrated the benefits of EXPAREL in improving a variety of key post-TJA outcomes including pain management, incidence of accidental falls, opioid consumption and hospital stay/costs. The AAOS 2014 meeting is being held in New Orleans from March 11-15.
News For PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
06:32 EDTPCRXPacira reports Q3 Exparel net product sales up 12% to $50.2M
Subscribe for More Information
06:31 EDTPCRXPacira reports Q3 non-GAAP EPS 16c, consensus 10c
Subscribe for More Information
October 27, 2014
16:03 EDTPCRXPacira EXPAREL use leads to significant reduction in opioid adverse events
Pacira Pharmaceuticals announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complications associated with opioid use. The data, presented at the American College of Surgeons, or ACS, Clinical Congress, found that patients treated with EXPAREL experienced statistically significantly lower rates of urinary retention, respiratory depression and fall risk compared to their counterparts who received the previous standard of care, or SOC. The ACS Clinical Congress is being held October 26-30 at the Moscone Center in San Francisco. The study evaluated 82 patients undergoing open ventral hernia repair or laparoscopic colon resection, all of whom were treated by Dr. Redan. Thirty-seven patients received the SOC: intravenous hydromorphone or morphine with or without epidurals and/or IV acetaminophen. The other 45 patients received infiltration with EXPAREL in addition to the SOC. of EXPAREL resulted in a statistically significant reduction (P<0.001) in the amount of patients classified as being “high-risk” for falls (8.4% in the EXPAREL group vs 16% in the SOC group) and an increase in patients classified as being “low-risk” for falls (48.7% in the EXPAREL vs 37.6% in the SOC group), according to the Morse Fall Scale designed to predict falls, and assess and address risk factors contributing to fall risk.
07:23 EDTPCRXAmerican College of Surgeons holds a conference
Subscribe for More Information
October 20, 2014
07:12 EDTPCRXCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use